학술논문

New combination therapies with subcutaneous epcoritamab in first-line therapy and in relapsed non-Hodgkin lymphoma. A phase 1b/2 multicenter, open-label study to assess safety, tolerability, and efficacy
Document Type
Journal
Source
ONCOLOGY RESEARCH AND TREATMENT; SEP 2022, 45 SUPPL 2, p196-p196, 1p. Supplement: 2
Subject
Language
English
ISSN
22965262